LIPOSOMAL DRY POWDER INHALER: NOVEL PULMONARY TARGETED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF LUNG CANCER

MANSING PATIL; PINKAL PATEL

doi:10.22159/ijap.2023v15i1.46611

Authors

MANSING PATIL Department of Quality Assurance, Parul Institute of Pharmacy & Research, Parul University, P.O. Limda, Tal. Waghodia, Dist. Vadodara, Gujarat 391760, India https://orcid.org/0000-0002-6831-5733
PINKAL PATEL Department of Quality Assurance, Parul Institute of Pharmacy & Research, Parul University, P.O. Limda, Tal. Waghodia, Dist. Vadodara, Gujarat 391760, India https://orcid.org/0000-0002-7876-8197

DOI:

https://doi.org/10.22159/ijap.2023v15i1.46611

Keywords:

Lung cancer, Lung targeted pulmonary drug delivery, Liposomal dry powder inhalers, Inhalation devices, Clinical trials, and Patents

Abstract

Lung cancer is a great evil doer behind mortality around the world. The degree of lung cancer patients in developing nations has grown from 31% to 49.9% over the recent 20 y. Despite current upgrades in lung cancer chemotherapy, the death rate in lung cancer patients is high. Generally, cancer chemotherapy is accompanied by most side effects. If an anticancer drug could deliver only the right site in the right concentration at the right time, cancer could be cured without side effects. A liposomal dry powder inhaler (LDPI) is an innovative strategy to convey drug particles. A dry powder inhaler (DPI) has unique features such as targeted drug delivery, improved bioavailability, and the better therapeutic efficacy of the embedded drug's ability to deliver the drug at a constant rate. This paper emphasizes the utility of liposomes and DPI in lung cancer therapy, commonly used formulation techniques for manufacturing LDPI, various devices used to deliver the therapeutic formulation, and ongoing and recently concluded clinical trials. Patents filed by multiple researchers and the future perspective of LDPI in an innovative drug delivery system and promising systems for administering a wide variety of drugs, including anti-cancer drugs, are described for lung cancer.

Downloads

Download data is not yet available.

References

Potter J, Higginson IJJ. Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. Lung Cancer. 2004;43(3):247-57. doi: 10.1016/j.lungcan.2003.08.030, PMID 15165082.

Kovacevic T, Kovacevic SV, Stanetic M, Kovacevic P, Miljkovic B. Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings. J Oncol Pharm Pract. 2021;27(2):350-8. doi: 10.1177/1078155220921545, PMID 32349642.

Subramanian J. Govindan RJJoco. Lung Cancer Never Smokers Rev. 2007;25(5):561-70.

Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AFJ. Jocb. Apoptosis Lung Cancer Rev. 2003;88(5):885-98.

Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst Schmidt W, Goldberg EP. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 2012;7:1551-72. doi: 10.2147/IJN.S29997, PMID 22619512.

Lee PN, Forey BA, Coombs KJJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer. 2012;12(1):385. doi: 10.1186/1471-2407-12-385, PMID 22943444.

Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist. 2008;13(3):309-19. doi: 10.1634/the oncologist.2007-0195, PMID 18378542.

Fathi Karkan S, Mohammadhosseini M, Panahi Y, Milani M, Zarghami N, Akbarzadeh A. Magnetic nanoparticles in cancer diagnosis and treatment: a review. Artif Cells Nanomed Biotechnol. 2017;45(1):1-5. doi: 10.3109/21691401.2016.1153483, PMID 27015806.

Charumathy A, Ubaidulla U, Sinha P, Rathnam G. Recent update on liposome-based drug delivery system. Int J Curr Pharm Sci. 2022;14(3):22-7. doi: 10.22159/ijcpr.2022v14i3.1991.

Bhattacharyya S, S Sogali B. Inhalation therapy–approaches and challenges. Asian J Pharm Clin Res. 2018;11(4):9-16. doi: 10.22159/ajpcr.2018.v11i4.24117.

Shetty A, Gjajpcr S. Advancements in dry powder inhaler. Asian J Pharm Clin Res. 2017;10(2):8-12.

Rajendran R, Balan R, Ganesan N, Djijpps T. Recent modalities in drug delivery via inhalation therapy–an advanced treatment strategy for pulmonary. Carcinoma. 2015;7:8-21.

Bonde S, Nair S. Advances in liposomal drug delivery system: fascinating types and potential applications. Int J App Pharm. 2017;9(3):1-7. doi: 10.22159/ijap.2017v9i3.17984.

Gauch R. It’s great! Oops, no it isn’t: why clinical research can’t guarantee the right medical answers. Springer; 2008.

Parsons A, Daley A, Begh R, Aveyard PJB. Influence of smoking cessation after diagnosis of early-stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340:b5569. doi: 10.1136/bmj.b5569, PMID 20093278.

Takkouche B, Gestal Otero JJJ. Ejoe. The Epidemiol Lung Cancer Rev Risk Factors Span Data. 1996;12(4):341-9.

Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889-902. doi: 10.1183/13993003.00359-2016, PMID 27174888.

Mao Y, Yang D, He J, Krasna MJ. Epidemiology of lung cancer. Surgical Oncology Clinics of North America. 2016;25(3):439-45. doi: 10.1016/j.soc.2016.02.001.

Wong MCS, Lao XQ, Ho KF, Goggins WB, Tse SLA Sr. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300. doi: 10.1038/s41598-017-14513-7, PMID 29085026.

Zappa C, Mousa SAJ. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288-300. doi: 10.21037/tlcr.2016.06.07, PMID 27413711.

Muhas C, Kumar P, Raja DJI. JoP, sciences P. Etiological Factors Dev Lung Cancer Non-Smokers Overview. 2019;11:10-6.

Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SCJC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2013;143(5):e278S-313S.

Ramalingam S, Belani CJTo. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. 2008;13Suppl 1:5-13.

Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest oncology group trial. J Clin Oncol. 2001;19(13):3210-8. doi: 10.1200/JCO.2001.19.13.3210, PMID 11432888.

Amini A, Yeh N, Gaspar LE, Kavanagh B, Karam SDJ. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review. Radiat Oncol. 2014;9(1):210. doi: 10.1186/1748-717X-9-210, PMID 25239200.

McLachlan JJP. Immune checkpoint inhibitors and their side effects. Pathology. 2019;51Suppl 17. doi: 10.1016/j.pathol.2018.12.036.

Jassem JJTlo. Comb chemother radiat locally adv nonsmall-cell lung cancer. Semin Oncol. 2001;2(6):335-42.

Burris HA. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene. 2009;28(1)Suppl 1:S4-S13. doi: 10.1038/onc.2009.196, PMID 19680296.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107, PMID 21296855.

Cruz CSD, Tanoue LT, Matthay RC. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44. doi: 10.1016/j.ccm.2011.09.001

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-64. doi: 10.3322/caac.21601, PMID 32133645.

Ward EM, Sherman RL, Henley SJ, Jemal A, Siegel DA, Feuer EJ. Annual report to the Nation on the status of cancer, featuring cancer in men and women age 20–49 Y. JNCI. 2019;111(12):1279-97. doi: 10.1093/jnci/djz106.

Stewart B, Wild C. IARC publications Website-world cancer report. Vol. 2014; 2014.

Malik PS, Raina VJT. Ijomr. Lung Cancer Prevalent Trends Emerg Concepts. 2015;141(1):5.

Mullin TMJFCfDE, Research. Patient-Focused Drug Development Public Meeting; 2012.

Miranda Filho A, Pineros M, Bray. F Jspdm. The Descript Epidemiol Lung Cancer Tob Control Glob Overview. 2019;61(3):219-29.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492, PMID 30207593.

Rudokas M, Najlah M, Alhnan MA. Elhissi AJMp, practice. Liposome delivery systems for inhalation: a critical review is highlighting formulation issues and anticancer applications. 2016;25Suppl 2:60-72.

Vanza J, Jani P, Pandya N, Tandel H. Formulation and statistical optimization of intravenous temozolomide-loaded pegylated liposomes to treat glioblastoma multiforme by three-level factorial design. Drug Dev Ind Pharm. 2018;44(6):923-33. doi: 10.1080/03639045.2017.1421661, PMID 29280385.

Kong G, Dewhirst MJI. JoH. Rev Hyperthermia Liposomes. 1999;15(5):345-70.

Shurtleff W, Aoyagi A. History of lecithin and phospholipids 1850-2016. Extensively annotated bibliography and sourcebook, including phosphatides and liposomes. Soyinfo Center; 2016.

Meure LA, Foster NR, Dehghani FJAP. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech. 2008;9(3):798-809. doi: 10.1208/s12249-008-9097-x, PMID 18597175.

Prime D, Atkins PJ, Slater A. Sumby BJAddr. Rev Dry Powder Inhalers. 1997;26(1):51-8.

Willis L, Hayes D, Mansour HMJL. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190(3):251-62. doi: 10.1007/s00408-011-9360-x, PMID 22274758.

Gaspar MM, Radomska A, Gobbo OL, Bakowsky U, Radomski MW, Ehrhardt C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J Aerosol Med Pulm Drug Deliv. 2012;25(6):310-8. doi: 10.1089/jamp.2011.0928, PMID 22857016.

Vanza JD, Shah DM, Patel RB, Patel MRJ. Afatinib liposomal dry powder inhaler: targeted pulmonary delivery of EGFR inhibitor for the management of lung cancer. Journal of Drug Delivery Science and Technology. 2022;74:103506.

Islam N, Gladki E. Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm. 2008;360(1-2):1-11. doi: 10.1016/j.ijpharm.2008.04.044. PMID 18583072.

Zhang T, Chen Y, Ge Y, Hu Y, Li M, Jin Y. Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B. 2018;8(3):440-8. doi: 10.1016/j.apsb.2018.03.004, PMID 29881683.

Lo Yl, Tsai JC, Kuo J-hJJocr. Liposomes disaccharides carriers spray-dried powder formulations superoxide dismutase. J Control Release. 2004;94(2-3):259-72.

Franze S, Selmin F, Samaritani E, Minghetti P, Cilurzo FJP. Lyophilization of liposomal formulations: still necessary, still challenging. Pharmaceutics. 2018;10(3):139. doi: 10.3390/pharmaceutics10030139, PMID 30154315.

Shah N, Shah V. Pulm drug deliv a promising approach. Journal of Applied Pharmaceutical Science 2012;2(6):33-7.

Cipolla D, Gonda I, Chan HK. Liposomal formulations for inhalation. Ther Deliv. 2013;4(8):1047-72. doi: 10.4155/tde.13.71, PMID 23919478.

Misra A, Jinturkar K, Patel D, Lalani J, Chougule M. Recent advances in liposomal dry powder formulations: preparation and evaluation. Expert Opin Drug Deliv. 2009;6(1):71-89. doi: 10.1517/17425240802652309, PMID 19236209.

Chougule M, Padhi B, Misra AJAP. Development of spray-dried liposomal dry powder inhaler of dapsone. AAPS PharmSciTech. 2008;9(1):47-53. doi: 10.1208/s12249-007-9024-6, PMID 18446460.

Joshi M, Misra AJC. Pharmacology e, physiology. Dispos Kinet Ketotifen Liposomal Dry Powder Inhal Rat Lung. 2003;30(3):153-6.

Akbarzadeh A, Rezaei Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi: 10.1186/1556-276X-8-102, PMID 23432972.

Laouini A, Jaafar Maalej C, Limayem Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, characterization and applications of liposomes: state of the art. J Coll Sci Biotechnol. 2012;1(2):147-68. doi: 10.1166/jcsb.2012.1020.

Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv. 2011;8(5):565-80. doi: 10.1517/17425247.2011.566552, PMID 21492058.

Wei H, Song J, Li H, Li Y, Zhu S, Zhou X. Active loading liposomal irinotecan hydrochloride: preparation, in vitro and in vivo evaluation. Asian Journal of Pharmaceutical Sciences. 2013;8(5):303-11. doi: 10.1016/j.ajps.2013.10.006.

Chougule MB, Padhi BK, Jinturkar KA, Misra AJR. Podd, formulation. Dev Dry Powder Inhalers. 2007;1(1):11-21.

Shah SP, Misra AJDD. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv. 2004;11(4):247-53. doi: 10.1080/10717540490467375, PMID 15371106.

Shah SP, Misra AJAP. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech. 2004;5(4):e65. doi: 10.1208/pt050465, PMID 15760062.

Kawasaki H, Shimanouchi T, Kimura YJJoc. Recent dev optim lyophilization process. Journal of Chemistry 2019(1):1-14. doi:10.1155/2019/9502856

Santos D, Mauricio AC, Sencadas V, Santos JD, Fernandes MH, Gomes PSJB-P. Spray drying: an overview; 2018. p. 9-35.

Adali MB, Barresi AA, Boccardo G, Pisano RJP. Spray freeze-drying as a solution to continuous manufacturing of pharmaceutical products in bulk. Processes. 2020;8(6):709. doi: 10.3390/pr8060709.

Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: A comprehensive review. Pharmaceutics. 2020;13(1):31. doi: 10.3390/pharmaceutics13010031, PMID 33379136.

Vanza JD, Patel RB, Patel MRJ. Nanocarrier centered therapeutic approaches: recent developments with insight towards the future in the management of lung cancer. Journal of Drug Delivery Science and Technology. 2020;60:102070. https://doi.org/10.1016/j.jddst.2020.102070

He Z, Ranganathan N, Li PJN. Evaluating nanomedicine with microfluidics. Nanotechnology. 2018;29(49):492001. doi: 10.1088/1361-6528/aae18a, PMID 30215611.

Dolovich MB, Dhand RJTL. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032-45. doi: 10.1016/S0140-6736(10)60926-9, PMID 21036392.

Chellappan DK, Sze Ning QL, Su Min SK, Bin SY, Chern PJ, Shi TP. Interactions between microbiome and lungs: paving new paths for microbiome-based bio-engineered drug delivery systems in chronic respiratory diseases. Chem Biol Interact. 2019;310:108732. doi: 10.1016/j.cbi.2019.108732, PMID 31276660.

Gaspar MM, Bakowsky U. Ehrhardt CJJoBN. Inhaled liposomes–curr strateg future chall. Journal of Biomedical Nanotechnology. 2008;4(3):245-57. doi: 10.1166/jbn.2008.334.

Reychler G, Leal T, Roeseler J, Thys F, Delvau N. Effect of continuous positive airway pressure combined to nebulization on lung deposition measured by urinary excretion of amikacin. Respir Med. 2007;101(10):2051-5. doi: 10.1016/j.rmed.2007.06.003.

Respaud R, Vecellio L, Diot P, Heuze Vourc’h N. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12(6):1027-39. doi: 10.1517/17425247.2015.999039, PMID 25557066.

Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci. 2003;19(5):443-55. doi: 10.1016/s0928-0987(03)00148-9, PMID 12907295.

ClinicalTrials.gov. United States national library of medicine. Niraparib in Combination with Osimertinib in EGFR-Mutated Advanced Lung Cancer; 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03891615. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. A study of EGF816 and gefitinib in TKI-naïve EGFR-mutant non-small cell lung cancer. United States National Library of Medicine; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03292133. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Lung cancer vaccine plus oral dietary supplement. United States National Library of Medicine; 2013. Available from: https://clinicaltrials.gov/ct2/show/NCT01829373. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Stepped palliative care versus early integrated palliative care in patients with advanced lung cancer (STEP PC). United States National Library of Medicine; 2022. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03337399. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Early integrated telehealth versus in-person palliative care for patients with lung cancer (REACH PC). United States National Library of Medicine; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03375489. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Safety and efficiency of γδ T cell against lung cancer. United States National Library of Medicine; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03183232. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Plus carboplatin-paclitaxel in squamous cell lung cancer. United States National Library of Medicine; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02513563. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Stereotactic body radiation for consolidation after standard chemoradiation for stage 3 lung cancer. United States National Library of Medicine; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT01656460. [Last accessed on 08 Nov 2022]

ClinicalTrials.gov. Radiotherapy and durvalumab/durvalumab combo (tremelimumab/olaparid) for small cell lung cancer. United States National Library of Medicine; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03923270. [Last accessed on 08 Nov 2022]

Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BEJ. Cc, pharmacology. Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol. 1999;44(3):177-86. doi: 10.1007/s002800050965.

Koshkina NV, Kleinerman ES, Walidrep C, Jia SF, Worth LL, Gilbert BE. 9-Nnitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res. 2000;6(7):2876-80. PMID 10914737.

Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V, Knight VJ. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001;7(10):3258-62. PMID 11595722.

Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer. 1997;79(7):1409-21. doi: 10.1002/(sici)1097-0142(19970401)79:7<1409::aid-cncr19>3.0.co;2-3. PMID 9083164.

Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D. Efficacy of nebulized liposomal amphotericin B in the treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother. 2005;49(7):3028-30. doi: 10.1128/AAC.49.7.3028-3030.2005, PMID 15980392.

Adler Moore J, Proffitt RTJ. AmBisome liposomal formulation struct mech action pre-clin experience. J Antimicrob Chemother. 2002;49(Suppl_1):21-30. doi: 10.1093/jac/49.suppl_1.21.

Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LNJ. Liposome deliv ciprofloxacin intracellular francisella tularensis infect. J Control Release. 2003 Oct 30;92(3):265-73. doi: 10.1016/s0168-3659(03)00358-4.

Huang YY, Wang CHJ. Pulm deliv insulin liposomal carriers. Journal of Orthopaedic Case Reports. 2006;113(1):9-14.

Karathanasis E, Bhavane R, Annapragada AVJ. Triggered release inhaled insulin agglomerated vesicles pharmacodyn stud rats. Journal of Orthopaedic Case Reports. 2006;113(2):117-27.

McLachlan G, Baker A, Tennant P, Gordon C, Vrettou C, Renwick L. Optimizing aerosol gene delivery and expression in the ovine lung. Mol Ther. 2007;15(2):348-54. doi: 10.1038/sj.mt.6300058, PMID 17235313.

Griesenbach U, Geddes DM, Alton EW. Gene therapy progress and prospects: cystic fibrosis. Gene Ther. 2006;13(14):1061-7. doi: 10.1038/sj.gt.3302809. PMID 16819538.

Wang Z, Orszanska H, Finlay W, Inventor. University of Alberta, Assignee; Spray freeze-dried liposomal ciprofloxacin powder aerosol drug delivery. United States patent US20060280691; 2006.

Stuart SB, Landon WL, Inventor. University of virginia, assignee; compositions and methods for detecting and treating cancer. United States patent US20130330274; 2013.

Rolf M. Inventor Vectron Therapeutics AG Affitech AS, assignee; liposomes and liposomal compositions for vaccination and drug delivery. United States patent US20070148220; 2007.

Susan N. Inventor; Johnson and Johnson Consumer Inc, Assignee. Method of manufacturing liposomes. United States patent US20020119188; 2002.

Gregory G. Inventor; UK secretary of state for defence, assignee. Method of forming liposomes. United States patent US9675554B1; 2017.

Ian M. Inventor; Arbutus biopharma corp, assignee. Systems and methods for manufacturing liposomes. United States patent US9005654B2; 2015.

Paul RM. Inventor; Elan Pharmaceuticals LLC Transave LLC, Assignee. Encapsulation of bioactive complexes in liposomes. United States patent US7491409B1; 2009.